Business Context and Reporting Period
Company: Atara Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2017
Event: Entry into a Material Definitive Agreement (Standard Industrial Lease).
Key Financial Metrics
This filing reports a material lease agreement rather than periodic financial performance. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics are not disclosed in this document.
| Lease Metric | Value |
|---|---|
| Leased Space | 90,580 rentable square feet |
| Location | Thousand Oaks, California |
| Initial Term | 15 years (Expected commencement: Q4 2017) |
| Base Rent (Year 1) | $74,422.00 per month |
| Base Rent (Year 15) | $112,569.95 per month |
| Renewal Options | Two options: 10 years and 9 years (subject to market adjustment) |
Material Changes
The filing discloses a new long-term operating commitment. The company will incur escalating monthly base rent payments starting in the fourth quarter of 2017, increasing from approximately $74,422 in the first year to approximately $112,570 in the fifteenth year. Additionally, the company is responsible for maintenance expenses, property management fees, taxes, and required insurance policies.
Outlook, Risks, and Contingencies
- Future Commitments: The lease creates a fixed cost obligation for up to 15 years, with potential extension to 34 years if renewal options are exercised.
- Market Risk: Rental rates for renewal terms are subject to market adjustment at the beginning of each renewal period.
- Documentation: The full text of the Lease agreement is not included in this 8-K but will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2017.
Investor Verification Checklist
- Verify the exact commencement date of the lease in the Q4 2017 Form 10-Q.
- Review the full Lease agreement (exhibit to Form 10-Q) for specific definitions of maintenance expenses, property management fees, and tax obligations.
- Assess the impact of the escalating rent schedule on the company's projected operating expenses and cash burn rate.
- Confirm the company's current liquidity position to ensure it can support the new fixed costs starting in late 2017.